RCKT
ROCKET PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.37
−3.71%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.47
From 52W high−36.42%
Volume1.58M
Market cap$369.94M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$3.47
From 52W high
−36.42%
Volume
1.58M
Market cap
$369.94M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
14.0x
P/E (TTM)
—
RSI (14)
45.4
MomentumView details →
1D Return
−3.71%
YTD Return
−2.14%
SummaryUpdated Jun 1, 2026
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a clinical-stage biotechnology company founded in 2015 and headquartered in Cranbury, New Jersey. The company specializes in developing gene therapies for rare and devastating genetic diseases, operating as a multi-platform biotechnology enterprise with both ex vivo and in vivo gene therapy programs. Since its initial public offering in February 2015, Rocket has focused exclusively on advancing innovative treatments for patients with limited therapeutic options, particularly those suffering from rare genetic disorders affecting blood cells, immune function, and organ systems.
Similar companies
Latest newsMore news →
Rocket Pharmaceuticals announced alignment with the U.S. Food and Drug Administration on continued enrollment and dosing and key elements of the global pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease, including a recalibrated dose.5d agoRocket Pharmaceuticals is advancing preparations for the launch of Kresladi, a gene therapy product.40d ago